Case series of complex therapy of hemoblastosis in the context of COVID-19

Introduction: The COVID-19 pandemic is a problem of a global scale, and it has an importance in modern oncology and hematology. Patients with cancer are at high risk of getting infected with COVID-19. Diagnosis of coronavirus infection in such patients entails the cancellation of chemotherapy for an indefinite period. A break between courses of treatment, as well as a complete cancellation of therapy, can increase the mortality of patients f rom oncohematological diseases. Material and methods: From June to October 2020, based on the Oncohematological Department of the National Research Oncology Center LLP, 19 patients were treated, of which: men-11, women-8. Average age-43 years (+-16). Of these, patients with multiple myeloma-32%; acute myeloid leukemia-26%; acute promyelocytic leukemia-11%; acute lymphoblastic leukemia-26%; chronic lymphocytic leukemia-5%. Treatment was carried out following the protocols for the diagnosis and treatment of hemoblastosis and concomitant COVID-19 infection. Results: This article presents clinical cases of complex therapy of patients with hemoblastosis and concomitant COVID-19 infection who were treated in a hospital.